| Name | Oxybuprocaine hydrochloride |
| Description | Oxybuprocaine hydrochloride (Oxybuprocaine HCl), a local anesthetic, is used especially in otolaryngology and ophthalmology. |
| In vivo | Similar to bupivacaine or lidocaine, Oxybuprocaine produces dose-related spinal cord blockade of proprioception, locomotion, and injury perception.Oxybuprocaine binds to sodium channels and reversibly stabilizes neuronal cell membranes to make them less permeable to sodium ions.Oxybuprocaine inhibits the depolarization of neuronal cell membranes, thereby Oxybuprocaine inhibits the depolarization of neuronal cell membrane, thus blocking the initiation and conduction of nerve impulses. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : 64 mg/mL (185.57 mM), Sonication is recommended. H2O : 63 mg/mL (182.67 mM), Sonication is recommended. DMSO : 64 mg/mL (185.57 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 2 mg/mL (5.8 mM), Sonication is recommended.
|
| Keywords | SodiumChannel | Sodium Channel | sclera | propagation | Parkinson's | painful | Oxybuprocaine hydrochloride | Oxybuprocaine | otolaryngology | ophthalmology | nerve | Na+ channels | Na channels | Inhibitor | inhibit | impulses | disease | cornea | conjunctiva | Benoxinate | ALO |
| Inhibitors Related | Phenytoin sodium | Procaine | Ranolazine dihydrochloride | Tetracaine hydrochloride | Lidocaine | Safinamide | Permethrin | Valproic Acid | L-Aspartic aicd sodium | Lidocaine hydrochloride | Mebeverine hydrochloride | Dibucaine |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Approved Drug Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |